Nazaj na portal Europarl

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (izbrano)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Ta dokument ni na voljo v vašem jeziku, zato v vrstici z jeziki izberite drugega.

Parliamentary questions
PDF 6kWORD 16k
6 July 2016
E-005523-16
Question for written answer E-005523-16
to the Commission
Rule 130
Mara Bizzotto (ENF) , Matteo Salvini (ENF)

 Subject:  Commission intervention to obtain justice for thalidomide victims
 Answer in writing 

On 25 June 2015, in response to Written Question E-010259/2015, ‘New actions of the Commission to support thalidomide victims’, the Commissioner for Health, Mr Andriukaitis, said that the Commission was considering taking ‘possible follow-up actions’ in order to meet the demands of European thalidomide victims.

A year later, 9 March, 2016, during the European Parliament part-session, Commissioner Andriukaitis himself reiterated the importance of ensuring that victims of thalidomide had financial support to cope with their increasingly large medical bills, recognising ‘the need to find a suitable solution for all survivors, which ensures their quality of life’.

Furthermore, in May 2015, the Canadian Government, assessing the long-term needs of 92 Canadian thalidomide survivors, decided to allocate an additional financial contribution of between 25 000 and 100 000 dollars a year to ensure they have a decent life and to cover their medical expenses.

In the light of Commissioner Andriukaitis' statements and following the example set by the Canadian Government, will the Commission not set up a negotiating table involving thalidomide victims, the Member States and Chemie Grunenthal, the company responsible for marketing the drug, with the aim of finally reaching a tangible solution to compensate and support the European victims of thalidomide?

Original language of question: IT 
Pravno obvestilo - Varstvo osebnih podatkov